Ion channel-enhancing nanoparticles reprogram T cells in vivo for cancer immunotherapy
In the authors' words
In head and neck squamous cell carcinoma (HNSCC), immunotherapy is frequently ineffective due to the impaired ability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. Kv1.3 potassium channels in T cells are essential for maintaining membrane potential, which is necessary for Ca2+ influx; however, they are suppressed within the tumor microenvironment, and no pharmacologic Kv1.3 activators are currently available. To address this limitation, we developed lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to specifically deliver mRNA encoding Kv1.3 (KCNA3) to T cells, thereby increasing channel expression and function. Treatment of human T cells with KCNA3-LNPs resulted in increased Kv1.3 channel protein levels and activity, leading to enhanced Ca2+ influx and elevated secretion of effector cytokines (IL-2, IL-17, TNF-, and IFN-{gamma}) and cytotoxic molecules (Granzyme A, Perforin, Granulysin, and Fas ligand). In a human peripheral blood mononuclear cell-engrafted HNSCC humanized mouse model, peritumoral delivery of KCNA3-LNPs significantly reduced tumor burden and increased the infiltration of CD8 Granzyme B cytotoxic T cells within the tumor, indicating improved antitumor immunity. Our study demonstrates that in vivo reprogramming of T cells through targeted Kv1.3 enhancement can overcome immunosuppressive barriers within the tumor microenvironment and enhance immune-mediated tumor clearance in vivo. This novel approach offers a scalable and cost-effective alternative to ex vivo T cell engineering and holds promise as a therapeutic strategy to improve immunotherapy outcomes in HNSCC and other solid tumors characterized by Kv1.3-dependent immune dysfunctions.
Appeared: Thursday, November 19. bioRxiv. Preprint, not yet peer-reviewed.